1249 related articles for article (PubMed ID: 14607757)
21. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
[TBL] [Abstract][Full Text] [Related]
22. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
Howman R; Barnes C; Curtin J; Price J; Robertson J; Russell S; Seldon M; Suppiah R; Teague L; Barrese G
Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
Rivard GE; Aledort L;
Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
[TBL] [Abstract][Full Text] [Related]
25. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
27. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
28. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
Schramm W
Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
[TBL] [Abstract][Full Text] [Related]
29. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients].
Kurth AA; Ludwig G; Scharrer I
Orthopade; 1999 Apr; 28(4):366-74. PubMed ID: 10335531
[TBL] [Abstract][Full Text] [Related]
30. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
Miesbach W; Krekeler S; Wolf Z; Seifried E
Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
[TBL] [Abstract][Full Text] [Related]
33. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
34. Major haemorrhage related to surgery in patients with type 1 and possible type 1 von Willebrand disease.
Woods AI; Blanco AN; Chuit R; Meschengieser SS; Kempfer AC; Farías CE; Lazzari MA
Thromb Haemost; 2008 Nov; 100(5):797-802. PubMed ID: 18989523
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
36. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
37. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
38. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease.
Meriane F; Zerhouni L; Djeha N; Goudemand M; Mazurier C
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1023-9. PubMed ID: 8148475
[TBL] [Abstract][Full Text] [Related]
39. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of hFVIII/VWF concentrate (Voncento
Rugeri L; d'Oiron R; Harroche A; Proulle V; Mourey G; De Raucourt E; Desprez D; Baikian NI; Petesch BP; Borel-Derlon A; Combe S; Frotscher B; Hassoun A; Catovic H; Bracquart D; Trossaërt M
Blood Transfus; 2021 Mar; 19(2):152-157. PubMed ID: 33263522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
